临床试验/NCT00070096

NCT00070096已完成2 期

A Phase II Study of BMS-247550 In Advanced Germ Cell Tumor Patients - THERAPEUTIC/DIAGNOSTIC PROTOCOL

Memorial Sloan Kettering Cancer Center1 个研究点分布在 1 个国家目标入组 29 人开始时间: 2003年8月最近更新: 2013年6月24日

适应症

试验速览

阶段: 2 期
状态: 已完成
发起方: Memorial Sloan Kettering Cancer Center
入组人数: 29
试验地点: 1
主要终点: Efficacy

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: This phase II trial is studying how well ixabepilone works in treating patients with metastatic germ cell tumors that are refractory to cisplatin.

详细描述

OBJECTIVES:

Determine the efficacy of ixabepilone in patients with metastatic cisplatin-refractory germ cell tumors.
Determine the safety of this drug in these patients.

OUTLINE: Patients receive ixabepilone IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 10-29 patients will be accrued for this study within 1.3-4 years.

研究设计

研究类型: Interventional
主要目的: Treatment
盲法: None

入排标准

年龄范围: 16 Years 至 —（Child, Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

未提供

排除标准

未提供

结局指标

主要结局

Efficacy

Safety

次要结局

未报告次要终点

研究者

发起方

Memorial Sloan Kettering Cancer Center

申办方类型

Other

研究点 (1)

Loading locations...

相似试验

已完成

2 期

Ixabepilone in Treating Patients With Metastatic Prostate CancerAdenocarcinoma of the ProstateRecurrent Prostate CancerStage IV Prostate Cancer

NCT00087139National Cancer Institute (NCI)124

已完成

2 期

Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial CancerEndometrial AdenocarcinomaRecurrent Endometrial CarcinomaStage IV Endometrial Carcinoma

NCT00095979National Cancer Institute (NCI)52

已完成

2 期

Ixabepilone in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal CancerPeritoneal Cavity CancerOvarian Cancer

NCT00030706Montefiore Medical Center

终止

1 期

Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast CancerBreast Cancer

NCT00765765University of Medicine and Dentistry of New Jersey6

已完成

2 期

Ixabepilone in Treating Patients With Locally Advanced or Metastatic Breast CancerBreast Cancer

NCT00045097National Cancer Institute (NCI)